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A B S T R A C T
Background: Restless legs syndrome is a sensorimotor disorder associated with several mental illnesses parti-
cularly depression.
Methods: A cross-sectional study of primary care patients. The prevalence of restless legs symptoms was studied
in 706 patients with depressive symptoms and 426 controls without a psychiatric diagnosis by using a structured
questionnaire. The depressive symptoms were evaluated with the BDI and the psychiatric diagnosis was con-
ﬁrmed by means of a diagnostic interview (M.I.N.I.). The subjects with elevated depressive symptoms were
divided into two groups subjects with depressive symptoms with and without clinical depression.
Results: The prevalence of restless legs symptoms was 24.8% in the controls, 50.0% in the patients with clinical
depression and 42.4% in the patients with depressive symptoms. CRP value was signiﬁcantly higher (p= .003)
in the clinically depressed patients than in the other groups. There was a higher concentration of TNF-α in the
subjects with restless legs symptoms (7.4 ng/l ± 3.2) compared with the subjects without symptoms (6.7 ng/
l ± 2.3)(p < .001). There was a signiﬁcant diﬀerence in the TNF-α levels between the subjects with and
without restless legs symptoms in the depression group (p < .001) and among the patients with depressive
symptoms but no a depression diagnosis (p= .022). In these groups, restless legs symptoms were associated with
elevated levels of TNF-α.
Conclusions: TNF-α level was associated with restless legs symptoms only among subjects with depressive
symptoms whether they had clinical depression or not. We suggest that TNF-α could be an underlying factor
between restless legs symptoms and comorbidities.
1. Introduction
Restless legs syndrome is a common sensorimotor disorder. Restless
legs symptoms are characterized by an unpleasant sensation in the legs
that appears at rest in the evening or during the night, but daytime
symptoms are not exclude. In addition, patients suﬀer from an urge to
move their legs and moving or stretching the legs relieves the symptoms
[1,2]. In previous studies, the prevalence of restless legs syndrome has
been between 4% and 29% [3]. Among primary care patients, the
prevalence has been found to be 24% to 25% [4,5]. Knowledge about
the pathophysiology of restless legs syndrome and clinical experience
have increased during the last decade, but the exact pathophysiology is
still obscure [6].
Several diﬀerent theories on the cause of restless legs syndrome
have been suggested, such as deﬁcient dopaminergic neurotransmis-
sion, iron deﬁciency, hormones, genetics, peripheral hypoxia, neu-
roinﬂammation and a lack of folate [7–12]. A lack of iron metabolism is
more about the central nervous system than the peripheral parts, it
aﬀects dopaminergic function, thereby disturbing monoamine neuro-
transmitter synthesis [9]. For its part this could explicate the presences
of depressive symptoms alongside of restless legs symptoms [13]. There
are numerous studies on the relationship between depressed mood or
depression and restless legs syndrome [14,15]. The fundamental causes
that binds depression and restless legs symptoms together is unresolved.
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Notwithstanding, the relationship between tumor necrosis factor
alpha (TNF- α) and depression is intricate. The activity of TNF-α is
possibly linked to several other diseases such as psoriasis, rheumatoid
arthritis and inﬂammatory bowel disease [16–18]. TNF-α is a member
of a superfamily of proteins and it is most accurately a pleiotropic cy-
tokine. TNF-α is a crucial factor intrinsic to the immune system's
proinﬂmmatory actions. Many divergent cells, e.g., activated macro-
phages, monocytes, T-cells, lymphocytes and astrocytes, have the ca-
pacity for produce TNF- α [17]. Major theories that have linked TNF- α
and depression together are revision on the hypothalamic-pituitary-
adrenal-axis, genetic polymorphisms and changes in serotonin and
dopamine transporters [19]. According to former studies, especially
elevated levels of TNF-α have not had a conclusive link to depression
[20–24], but this connection invariably exists [25,26]. The relation
between TNF-α and restless legs syndrome has proved to be insignif-
icant [27].
Previously, a commonly used inﬂammation marker— C reactive-
protein (CRP)— activates the synthesis of interleukin-6 and TNF-α and
most of all is associated with bacterial inﬂammation, tissue injury or
stress but CRP has been found to be connected to depression [28,29].
The relationship between CRP and restless legs syndrome was negli-
gible in a previous study [30]. However, another study suggested that
systemic low-grade inﬂammation might play a role in restless legs
symptoms [27]. Thus, inﬂammation could be one factor linking restless
legs symptoms to depression. A relationship between depression, rest-
less legs symptoms and inﬂammation markers, including CRP and TNF-
α, has not been studied before at lenght thus the relationship required
more searching.
Aims
Due to non-existent data on the correlation between TNF-α, restless
legs symptoms and a diagnosis or symptoms of depression, we decided
to study this relationship in a geographically deﬁned sample of patients
with depressive symptoms with and without clinical depression and
population-based control subjects without a psychiatric diagnosis. We
hypothesized that TNF-α may have a role in the elevated presentation
of restless legs symptoms among depressed subjects.
2. Material and methods
New patients aged 35 years or older who went themselves or were
referred by a general practitioner to a depression nurse case manager in
2008–2009 due to depressive symptoms and a score of least 10 in the
21-item Beck's Depression Inventory (BDI) were enlisted in this study.
Altogether 706 patients were involved. The study (the Finnish
Depression and Metabolic Syndrome in Adults study, FDMSA) was
conducted in municipalities belonging to the Central Finland Hospital
District, with a catchment area of 274,000 residents. Notiﬁcation was
based on written and oral patient information and written consent was
obtained before any study procedures. The study protocol was ap-
proved by the Ethics Committee of the Central Finland Hospital District.
The FDMSA -study has been reported in previous studies [31–35].
Random sampling was used to select a group of 426 middle-aged
(> 35 years) persons as controls from among residents in the partici-
pating municipalities. Concurrently with the patient recruitment in
2008–2009, an age, sex and community stratiﬁed random sample re-
presenting the population in the study region was taken by Statistics of
Finland (http://www.stat.ﬁ). Statistics of Finland is independent or-
ganization under the Ministry of Finance and manages the data from
administrative registers in Finland. All the subjects in the control group
had a BDI score below 10 and no psychiatric diagnosis or current de-
pressive symptoms and they used no psychoactive medications. A total
of 27 subjects in the study groups did not answer the question about
restless legs symptoms. To eschew misrepresented results, the data do
not include subjects (N=78) c-reactive protein (CRP) values over
30mg/l or TNF-α values over 50 ng/l, ensuring that microbe based
contamination would not excessively impact the results [36,37].
All the participants ﬁlled in a standard questionnaire form con-
taining questions about previously diagnosed somatic disorders and use
of medications, including antidepressants and hormone replacement
therapy in females. Data on current smoking, years of education, use of
alcohol (number of drinks per week) and leisure-time physical activity
(number of 30-min exercise sessions) were also collected. Leisure-time
physical activity was determined with the question:” How often do you
do physical activity at least half on hour so that you are out of breath
and sweating?” then answers were classiﬁed as low (0–2 sessions per
month), moderate (1–2 sessions per week), or high (three or more
sessions per week) [35].
The depressive symptoms were evalueted with the 21-item Beck's
Depression Inventory (BDI) [38], which was completed by the partici-
pants. The psychiatric diagnosis was conﬁrmed with a diagnostic in-
terview (Mini-International Neuropsychiatric Interview; M.I.N.I. [39])
conducted by a trained study nurse [40]. Out of the whole study po-
pulation, 439 subjects had a BDI score of 10 or higher and a diagnosis of
depression determined with the diagnostic interview (M.I.N.I.)
[39,41,42].
Restless legs symptoms were detected with a structured and tested
question that takes into account the core characteristics of restless legs
syndrome discomfort: an urge to move the legs, primarily during rest or
inactivity, and partial or total relief with movement, with the presence
or worsening of discomfort exclusively in the evening or at night.
According to a previous validation study, the questionnaire had 100%
sensitivity and 96.8% speciﬁcity. Moreover, the likelihood ratio for a
positive result (LR+=31,25) adverted to the positive test had a con-
clusive elevate in the probability of restless legs syndrome [43].
The blood sample collection procedure happened in the health
centre's laboratories by educated nurse and in an outpatient setting.
Glucose and lipid level determinations were based on fasting blood
samples drawn between 8 and 11 o'clock after 12 h of fasting. TNF-α
was determined from freezed samples and cocentration was analyzed
using an Immulite 1000 immunoassay analyzer (Siemens Healthcare
Diagnostics Products Ltd., Gwynedd, UK). Serum total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides and plasma glucose were
analyzed using Modular Analytics SWA (Hitachi High-Technologies
Corporation, Tokyo, Japan).
2.1. Statistical analysis
Statistical comparisons between the groups was done by analysis of
variance (ANOVA), Kruskal-Wallis test, Chi-Square test or Fisher-
Freeman-Halton test, when appropriate. When adjusted models were
used, analysis of covariance (ANCOVA) was applied; the models in-
cluded age, smoking, alcohol use, body mass index and physical activity
as covariates. In the case of violation of the assumptions (e.g. non-
normality), a bootstrap-type method was used (10,000 replications) to
estimate standard error. The normality of variables was evaluated by
the Shapiro-Wilk W test. All the analyses were performed using STATA
15.0.
3. Results
A total of 1027 subjects, comprising the patients and controls,
participated in our study; (33.0%) men and 688 (67.0%) women. Of
these subjects, 396 were controls with no psychiatric diagnosis, 243
were patients with depressive symptoms without a depression diagnosis
and 388 patients had received a depression diagnosis. All the subjects
with elevated depressive symptoms and the clinically depressed pa-
tients had higher triglyceride levels, lower leisure time physical activity
and higher body mass index (BMI) than the controls. Furthermore, the
prevalence of current smoking was higher in the patient groups than in
the controls. The clinically depressed patients had a signiﬁcally higher
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plasma glucose values and CRP than the controls. (Table 1).
Restless legs symptoms were present in 395 (38.5%) of the study
subjects. There was a signiﬁcant diﬀerence in the prevalence of restless
legs symptoms between study groups (P < .001; adjusted for sex, age,
smoking, alcohol use, BMI and physical activity). The controls had the
lowest prevalence of restless legs symptoms: 24.8%. The patients with
depressive symptoms without a depression diagnosis had a 42.4%
prevalence of restless legs symptoms and the highest prevalence 50.0%
was found among the clinically depressed patients.
The average concentration of TNF-α was 7.0 ng/l. There was no
noteworthy diﬀerence in the concentration of TNF-α between the
controls and the depressive patients groups. The concentration of TNF-
α was statistically signiﬁcantly higher in the subjects with restless legs
symptoms (7.4 ng/l ± 3.2) as compared to the subjects without restless
legs symptoms (6.7 ng/l ± 2.3)(p < .001 adjusted for sex, age,
smoking, alcohol use, body mass index and physical activity).
Fig. 1 shows that in general there was a signiﬁcant diﬀerence
(p= .005) in the levels of TNF-α between the subjects with and without
restless legs symptoms. In the clinically depressed patients (p= .005)
and among the patients with depressive symptoms without a depression
diagnosis (p= .006) restless legs symptoms were signiﬁcantly asso-
ciated with elevated levels of TNF-α. However, among the control
subjects, the TNF-α levels were similar with and without restless legs
symptoms. Furthermore we discovered not signiﬁcant diﬀerence in
concentration of TNF-α between atypical and melancholic depression
subtypes, regardless of restless legs symptoms. There were no diﬀer-
ences in TNF-α levels between the patient groups and the controls if
restless legs symptoms was not taken into consideration. The other
marker of inﬂammation, CRP, did not have a similar association to
restless legs symptoms.
4. Discussion
The novel ﬁnding in our study was that in the subjects with
depressive symptoms with and without clinical depression, elevated
circulating TNF-α was found only in those with having restless legs
symptoms. Contrary to that ﬁnding, the levels of TNF-α were similar in
the control group regardless of restless legs symptoms. Based on these
results, we propose that TNF-α may have a noteworthy role in the
manifestation of restless legs symptoms, particularly in depressive pa-
tients.
The prevalence of restless legs symptoms was 24.8% in the controls.
Respectively, previous population studies have reported the prevalence
of restless legs syndrome that estimates as high as 24% [43–45], and
among patients with depression the prevalence that estimates as high as
31.5% [46]. The association between TNF- α and depression is not
signiﬁcant constantly; for instance, obesity may confuse the corre-
spondence [47]. The present study suggests that among people with
depressive symptoms or clinical depression, elevated circulating TNF- α
levels are linked to a comorbid background factor such as manifesting
as restless legs symptoms.
Previous studies have found TNF-α potency to initiate divalent
metal transporter 1 (DMT1) onset, whereupon iron uptake increase in
the astrocytes, microglia and neurons [48,49]. Iron has an inﬂuence on,
e.g., DNA synthesis and protein metabolism including dopamine and
serotonin synthesis [50]. Another conceivable theory is connected to
TNF-α's impact on monoaminergic systems, including the functions of
dopamine and serotonin. Elevated plasma TNF-α improved in-
doleamine 2,3-dioxygenase (IDO) activity in peripheral and brain tis-
sues [51]. IDO precipitated depression inhibiting development of
tryptophan to serotonin [52] and TNF-α decreased the bioavaibility of
serotonin and had an eﬀect on reuptaking of serotonin [53].
Previous studies have shown that anti-TNF-α treatment, precisely
inﬂiximab, diminished depressive symptoms or depression in patients
with other diseases, e.g., Crohn's disease and ankylosing spondylitis,
and the activity of the disease did not have an impact on outcome
[54,55]. Inﬂiximab relieved depression-like behavior in mice [51], but
in a patient study inﬂiximab did not enhance treatment-resistant
Table 1
Demographic and clinical traits of the subjects.
Controls (A) BDI ≥10 P-value
N=396 Without depression (B)
N=243
Depression (C)
N=388
Female, n (%) 234 (59) 180 (74) 274 (71) < 0.001
Age, mean (SD) 53 (10) 54 (11) 51 (10) 0.002
Education years, mean (SD) 11.9 (3.4) 11.0 (3.3) 11.0 (3.1) < 0.001
Body Mass Index, mean (SD) 26.7 (4.6) 27.9 (6.0) 27.9 (5.6) 0.005
Smoking, n (%) 64 (16) 56 (23) 127 (33) < 0.001
Alcohol use dose, n (%) 0.088
0 65 (16) 58 (24) 91 (23)
1–9 282 (71) 158 (65) 248 (64)
≥10 49 (12) 27 (11) 49 (13)
Leisure time physical activity, n (%) < 0.001⁎
Low 46 (12) 40 (17) 98 (25)
Moderate 173 (44) 118 (49) 157 (41)
High 177 (45) 84 (35) 132 (34)
BP, mmHg, mean (SD)
Systolic 129 (16) 130 (16) 130 (16) 0.50
Diastolic 81 (10) 81 (10) 82 (10) 0.58
Plasma glucose, mmol/l, mean (SD) 5.67 (0.99) 5.64 (0.86) 5.85 (1.37) 0.042
Serum cholesterol, mmol/l, mean (SD) 5.05 (0.88) 5.12 (0.95) 5.09 (1.03) 0.67
Serum LDL cholesterol, mmol/l, mean (SD) 3.11 (0.82) 3.11 (0.84) 3.05 (0.94) 0.66
Serum HDL cholesterol, mmol/l, mean (SD) 1.57 (0.42) 1.57 (0.45) 1.57 (0.48) 0.99
Serum triglycerides, mmol/l, mean
(SD)
1.21 (0.66) 1.37 (1.65) 1.36 (0.83) 0.012
C-reactive protein, mg/l (SD) 2.62 (3.41) 2.58 (3.31) 3.55 (4.84) 0.003
Tumor necrosis factor alpha (SD) 6.9 (2.7) 7.1 (3.2) 7.0 (2.4) 0.65
Antidepressant medication (%) 20 (5) 118 (49) 267 (69) < 0.001
Results in the table shown as numbers (percentage) and means (standard deviation).
SD, standard deviation; BMI, body mass index; alcohol dose, 12 g of pure alcohol; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
⁎ low p < .001, moderate p= .13 and high p < .001.
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depression [56]. Could we consider the use of anti-TNF-α treatment for
depression as a cause of grievous restless legs symptoms? Conceivable
drawbacks of anti-TNF-α treatment are infections [57], whereupon, a
disadvantage of the treatment is that it hinders rather than helps.
In our study, the clinically depressed patients had higher CRP levels
than the controls, which has been common for CRP also in previous
studies [58]. The data showed that CRP level did not have an inﬂuence
on the occurence of restless legs symptoms in the depressive patients.
Our ﬁnding suspected the pathophysiology of restless legs symptoms to
includ eﬀects of the immune system, but the association between CRP
and restless legs symptoms was not the most likely alternative [59].
There was strong evidence that CRP is a more probabilistic immune
marker alternative, overarching to unambiguous depression, than TNF-
α [24].
The strengths of our investigation included a geographically re-
presentative sample of middle-aged and elderly subjects. Moreover, the
diagnosis of depression was based on a diagnostic interview besides
self-reported depressive symptoms. However, the diagnostic interview
did not contain questions about restless legs symptoms. The data re-
garding restless legs symptoms were based on structured questionnaire
enquiring about self-reported symptoms. The study did not take into
consideration diﬀerentiating between idiopathic, secondary, or iatro-
genic restless legs symptoms, which is a limitation.
It can be possible that simple sentence questionnaire with a high
sensitivity and speciﬁcity endorsed by Ferri et al. in 2007 could cause
false positive responses [43]. However, it is comparable with some
other studies using criteria developed by International Restless Legs
Syndrome Study Group [44]. Another limitation is the cross-sectional
design of our study, which does not justify making inferences of the
causality of TNF-α and restless legs symptoms. Additionally, only per-
sons aged 35 or older were enrolled in the study, so the results can not
be generalized to younger age groups.
These ﬁndings suggest a role for neuroinﬂammation in the genesis
of restless legs symptoms in the patients with depressive symptoms with
and without clinical depression but diﬀerentiating and origin of the
restless legs symptoms require further clariﬁcation. This study may
have some clinical implications and it prompts further studies because
to our knowledge this is the ﬁrst study that has presented a relationship
between TNF-α and restless legs symptoms in depressive patients. We
conclude that based on the present results elevated circulating TNF-α
levels are associated with restless legs symptoms in subjects with de-
pressive symptoms with and without clinical depression, but not in
subjects with no depressive symptoms.
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